Onkologie, Hämatologie - Daten und Informationen

2 Begleitmaßnahmen bei definierter medikamentöser Therapie: Literatur

Autor/en: H.-P. Lipp, C. Bokemeyer, J.T. Hartmann
Letzte Änderung: 25.01.2006
  • Abid SH, Malhotra V, Perry MC.
    Radiation-induced and chemotherapy-induced pulmonary injury.
    Current Opinion in Oncology 2001;13:242-248. PM:11429481

  • Anand AJ, Bashey B.
    Newer insights into cisplatin nephrotoxicity.
    Ann Pharmacother 1993;27:1519-1525. PM:8305788

  • Andre T, Figer A, Cervantes A, Lledo G, Flesch M, Maindrault-Goebel F, Mineur L, Russ G, Buyse M, De Gramont A.
    FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study.
    Proc Am Soc Clin Oncol 2003;22: Abstract #1016.

  • Bearman SI.
    Veno-occlusive disease of the liver.
    Current Opinion in Oncology 2000;12:103-109. PM:10750719

  • Boyle FM, Wheeler HR, Shenfield GM.
    Glutamine ameliorates experimental vincristine neuropathy.
    J Pharmacol Exp Therap 1996;279:410-415. PM:8859020

  • Burns LJ.
    Ocular toxicities of chemotherapy.
    Semin Oncol 1992;19:492-500. PM:1411647

  • Busea JM, Garcia-Teijido P, Losa R et al.
    Treatment of ifosfamide encephalopathy with intravenous thiamin.
    Clin Cancer Res 2003;9:4636-4637. PM:14555540

  • Cerosimo RJ.
    Monoclonal antibodies in the treatment of cancer, part 1.
    Am J Health Syst Pharm 2003;60:1531-1548.

  • Cianci G, Morelli MF, Cannita K.
    Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.
    Br J Cancer 2003;88:1507-1509. PM:12771913

  • Coleman R, Santoso JT, Lucci J.
    Saline, mannitol, and furosemide in acute cisplatin nephrotoxicity: a randomized trial. Proc Am Soc Clin Oncol 2003; 22: Abstract #1892.

  • Cvitkovic E.
    Cumulative toxicities from cisplatin therapy and current cytoprotective measures.
    Cancer Treat. Rev 1998;24:265-281. PM:9805507

  • De Jongh FE, van Veen RN, Veltman SJ.
    Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients.
    Br J Cancer 2003;88:1199-1206. PM:12698184

  • Drachtman RA, Cole PD, Golden CB.
    Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002;19:319-327. PM:12078863

  • Durant J-P, Brezault C, Goldwasser F.
    Protection against oxaliplatin acute neurosensory toxicity by venlafaxine.
    Anti-Cancer Drugs 2003;14:423-425. PM:12853883

  • Durant J-P, Goldwasser F.
    Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine.
    Anti-Caner Drugs 2002;13:777-780. PM:12187335

  • Foladore S, Ceccherini R, Leita M.
    Gabapentin in chemo-induced peripheral neuropathy prevention: A phase II open study. Proc Am Soc Clin Oncol 2003;22: Abstract #3089.

  • Gamelin E, Gamelin L, Bossi L, Quasthoff S.
    Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures.
    Semin Oncol 2002;29:21-33. PM:12422305

  • Gamelin E, Gamelin L, Delva R, Guerin-Meyer V, Morel A, Boisdron-Celle M.
    Prevention of oxaliplatin peripheral sensory neuroathy by Ca gluconate Mg chloride infusions: a retrospective study.
    Proc Am Soc Clin Oncol 2002;21: Abstract #624.

  • Hartmann JT, Benöhr P, Krueth P, Kanz L, Bokemeyer C, Osswald H.
    A randomised, placebo-controlled trial of theophylline to protect from cisplatin-induced glomerular renal damage.
    Onkologie 2003;26: Abstract #V148.

  • Hartmann JT, Lipp H-P.
    Toxicity of platinum compounds.
    Expert Opin Pharmacother 2003;4:889-901. PM:12783586

  • Herishanu Y, Lishner M, Kitay-Cohen Y.
    The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.
    Anti-Cancer Drugs 2002;13:177-179. PM:11901312

  • Koukourakis MI.
    Amifostine in clinical oncology: current use and future applications.
    Anti-Cancer Drugs 2002;13:181-209. PM:11984063

  • Krackhardt A, Schwartz S, Korfel A, Thiel E.
    Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure.
    Leukemia Lymphoma 1999;35:631-635. PM:10609804

  • Kreisman H, Wolkove N.
    Pulmonary toxicity of antineoplastic therapy.
    Semin Oncol 1992;19:508-520. PM:1411649

  • Levi F, Zidane R, Misser JL.
    Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer.
    Lancet 1997;350:681-686. PM:9291901

  • Lipp H-P, Bokemeyer C.
    Clinical pharmacokinetics of cytostatic drugs: Efficacy and toxicity.
    In: Lipp H-P (ed). Anticancer drug toxicity: Prevention, management and clinical pharmacokinetics. New York, Basel: Marcel Dekker 1999;11-201.

  • Maestri A, De Pasquale Ceratti A, Calandri C.
    Acetyl-L-carnitine in patients with chemotherapy-induced peripheral sensory neuropathy. Proc Am Soc Clin Oncol 2002;21: Abstract #2807.

  • Mielke S, Mross K, Gerds TA.
    Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anti-Cancer Drugs 2003;14:785-792. PM:14597872

  • Nicolao P, Giometto B.
    Neurological toxicity of ifosfamide.
    Oncology 2003;65:11-16. PM:14586141

  • Nissim I, Weinberg JM.
    Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats.
    Kidney Int 1996;49:684-695. PM:8648909

  • O'Sullivan JM, Huddart RA, Norman AR.
    Prediciting the risk of bleomycin lung toxicity in patients with germ-cell tumours.
    Ann Oncol 2003;14:91-96. PM:12488299

  • Pace A, Savarese A, Picardo M.
    Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin.
    J Clin Oncol 2003;21:927-931. PM:12610195

  • Pelgrims J, De Vos F, Van den Brande J.
    Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
    Br J Cancer 2000;82:291-294. PM:10646879

  • Peltier AC, Russell JW.
    Recent advances in drug induced neuropathies.
    Curr Opin Neurol 2002;15:633-638. PM:12352008

  • Perez EA, Rodeheffer R.
    Clinical cardiac tolerability of trastuzumab.
    J Clin Oncol 2004;22:322-329. PM:14722042

  • Perry MC.
    Hepatotoxicity of chemotherapeutic agents.
    Semin Oncol 1982;9:65-74. PM:7071610

  • Pisano C, Pratesi G, Laccabue D.
    Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.
    Clin Cancer Res 2003;9:5756-5767. PM:14654561

  • Quinn CT, Griener JC, Bottiglieri T.
    Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer.
    J Clin Oncol 1997;15:2800-2806. PM:9256122

  • Rowinski EK, Chaudhry V, Cornblath DR.
    Neurotoxicity of taxol.
    J Natl Cancer Inst 1993;15:107-115. PM:7912516

  • Savarese DMF, Savy G, Vahdat L, Wischmeyer PE, Corey B.
    Prevention of chemotherapy and radiation toxicity with glutamine.
    Cancer Treat Rev 2003;29:501-513. PM:14585260

  • Sayer HG, Will U, Schilling.
    Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation - successful treatment with high-dose methylprednisolone and defibrotide.
    J Cancer Res Clin Oncol 2002;128:148-152. PM:11935301

  • Schilsky RL, Desai A, Creaven P, Berghorn E, Ratain M, Hausheer F.
    BNP7787 permits safe administration of paclitaxel and cisplatin without IV hydration.
    Proc Am Soc Clin Oncol 2003;22: Abstract #594.

  • Shamash J, Earl H, Souhami R.
    Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate.
    Cancer Chemother Pharmacol. 1991;28;150-151. PM:2060085

  • Skinner R.
    Nephrotoxicity and urotoxicity of chemotherapeutic agents.
    In: Lipp H-P (ed). Anticancer drug toxicity: Prevention, management and clinical pharmacokinetics.
    Basel, New York: Marcel Dekker 1999;321-346.

  • Skinner R.
    Strategies to prevent nephrotoxicity of anticancer drugs.
    Curr Opin Oncol 1995;7:310-315. PM:7578377

  • Stanford BL, Zondor SD.
    Bortezomib treatment for multiple myeloma.
    Ann Pharmacother 2003;37:1825-1830. PM:14632585

  • Swain SM, Vici P.
    The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
    J Cancer Res Clin Oncol 2004;130:1-7. PM:14564513

  • Takimoto CH, Lu Z-H, Zhang R, Liang MD.
    Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency.
    Clin Cancer Res 1996;2:477-481. PM:9816193

  • Tuxen MK, Hansen SW.
    Neurotoxicity secondary to antineoplastic agents.
    Cancer Treat Rev 1994;20:191-214. PM:8156541

  • Vahdat L, Papadopoulos K, Lange D.
    Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
    Clin Cancer Res 2001;7:1192-1197. PM:11350883

  • Verschraagen M, Boven E, Ruijter R.
    Pharmacokinetics and preliminary clinical data of the novel chemoprotector BNP7787 and cisplatin and their metabolites.
    Clin Pharmacol Ther 2003;74:157-169. PM:12891226

  • Verschraagen M, Kedde MA, Hausheer FH, van der Vijgh WJ.
    The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
    Cancer Chemother Pharmacol 2003;51:499-504. PM:12715205

  • Wang MS, Davis AA, Culver DG, Glass JD.
    WldS mice are resistant to paclitaxel (taxol) neuropathy.
    Ann Neurol 2002;52:442-447. PM:12325073

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag